BackgroundThe selective serotonin reuptake inhibitor fluoxetine (FLX) is widely used to
treat depression and anxiety disorders, but cellular mechanisms underlying
the antidepressant effect of FLX remain largely unknown. The generally
accepted effect of chronic FLX treatment is increased adult neurogenesis in
the hippocampal dentate gyrus. It was recently demonstrated that FLX
treatments can reverse the established neuronal maturation of granule cells
in the hippocampal dentate gyrus and of gamma-aminobutyric acidergic
(GABAergic) interneurons in the basolateral amygdala. However, it is not
clear whether this dematuration effect of FLX occurs in other brain regions.
Thus, in this study, we used immunohistological analysis to assess the
effect of FLX treatment on GABAergic interneurons in the medial frontal
cortex (mFC) and reticular thalamic nucleus (RTN).ResultsImmunofluorescence analysis for perineuronal nets (PNNs), which is a marker
of neuronal maturation, and for parvalbumin, calretinin, and somatostatin,
which are markers for specific GABAergic interneuron type, showed lower
number of parvalbumin-positive (+) cells and PNN+/parvalbumin+ cells
in the mFC of FLX-treated mice compared to vehicle-treated mice. However,
FLX treatment had no effect on the number of cells expressing calretinin and
somatostatin in the mFC. In the RTN, the number of PNN+ cells and
parvalbumin+ cells was unaltered by FLX treatments. Furthermore, the
number of total GABA+ cells and apoptotic cells in the mFC was similar
between vehicle- and FLX-treated mice, suggesting that FLX treatment did not
induce cell death in this region. Rather, our findings suggest that the
decreased number of parvalbumin+ cells in the mFC was due to a
decreased expression of parvalbumin proteins in the interneurons.ConclusionsThis study indicates that FLX decreases the levels of parvalbumin, a mature
marker of fast-spiking interneurons, and PNNs in parvalbumin+ interneurons
in the mFC, suggesting that FLX treatment induces a dematuration of this
type of neurons. Induction of a juvenile-like state in fast-spiking
inhibitory interneurons in these regions might be involved in the
therapeutic mechanism of this antidepressant drug and/or some of its adverse
effects.